A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 06 2021
Historique:
received: 21 05 2020
revised: 22 12 2020
accepted: 11 02 2021
pubmed: 17 2 2021
medline: 5 11 2021
entrez: 16 2 2021
Statut: ppublish

Résumé

Targeted monotherapies usually fail due to development of resistance by a subgroup of cells that evolve into recurrent tumors. Alveolar rhabdomyosarcoma is an aggressive myogenic soft-tissue cancer that is associated with a characteristic

Identifiants

pubmed: 33589519
pii: 0008-5472.CAN-20-1613
doi: 10.1158/0008-5472.CAN-20-1613
pmc: PMC8178207
mid: NIHMS1675840
doi:

Substances chimiques

Biomarkers, Tumor 0
FGF8 protein, human 0
Oncogene Proteins, Fusion 0
PAX3-FOXO1A fusion protein, human 0
Paired Box Transcription Factors 0
Fibroblast Growth Factor 8 148997-75-5

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2930-2942

Subventions

Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC011387
Pays : United States

Informations de copyright

©2021 American Association for Cancer Research.

Références

Cancer Res. 1998 May 15;58(10):2053-6
pubmed: 9605740
Oncogene. 2018 Apr;37(15):1991-2007
pubmed: 29367756
Oncogene. 2002 Aug 1;21(33):5069-80
pubmed: 12140757
J Transl Med. 2019 Mar 20;17(1):96
pubmed: 30894200
Clin Pharmacol Drug Dev. 2018 Jun;7(5):532-542
pubmed: 29346833
J Thorac Oncol. 2011 Dec;6(12):2011-7
pubmed: 22052230
Carcinogenesis. 2014 May;35(5):1144-53
pubmed: 24464787
Transl Oncol. 2017 Jun;10(3):332-339
pubmed: 28340475
Breast Cancer Res. 2019 Aug 5;21(1):87
pubmed: 31383035
PLoS One. 2015 Oct 14;10(10):e0140528
pubmed: 26466313
Crit Rev Oncog. 2012;17(1):1-16
pubmed: 22471661
Am J Pathol. 2009 Dec;175(6):2600-8
pubmed: 19893043
Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):257-66
pubmed: 17512240
Mol Cell Biol. 2006 Nov;26(21):8109-21
pubmed: 16908535
Oncogene. 2011 Mar 31;30(13):1518-30
pubmed: 21119603
Oncol Rep. 2009 Jan;21(1):211-6
pubmed: 19082464
Lancet Oncol. 2007 Nov;8(11):1018-29
pubmed: 17976612
Mol Cancer Ther. 2009 Aug;8(8):2152-62
pubmed: 19671734
Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):8928-32
pubmed: 1409588
Oncogene. 2016 Mar 31;35(13):1671-8
pubmed: 26096932
Nat Genet. 1993 Feb;3(2):113-7
pubmed: 8098985
Oncogene. 2001 Sep 10;20(40):5736-46
pubmed: 11607823
J Hematol Oncol. 2019 Jun 21;12(1):63
pubmed: 31227004
Cancer Discov. 2017 Aug;7(8):884-899
pubmed: 28446439
Clin Cancer Res. 2014 Jun 1;20(11):2846-50
pubmed: 24727321
Clin Cancer Res. 2015 Nov 1;21(21):4947-59
pubmed: 25810375
Front Cell Dev Biol. 2016 Oct 18;4:110
pubmed: 27803896
Oncol Rep. 2017 Oct;38(4):2205-2210
pubmed: 28791365
J Cancer Res Clin Oncol. 2019 Jan;145(1):77-86
pubmed: 30276721
Cancer. 2009 Sep 15;115(18):4218-26
pubmed: 19536876
Nat Med. 2001 Feb;7(2):235-9
pubmed: 11175856
J Pathol. 2017 Apr;241(5):626-637
pubmed: 28138962
Clin Cancer Res. 2005 May 15;11(10):3897-904
pubmed: 15897591
Cancer Biol Med. 2018 Feb;15(1):14-28
pubmed: 29545965
Mol Cancer Ther. 2013 Dec;12(12):2663-74
pubmed: 24107448
Curr Pharm Des. 2014;20(5):793-807
pubmed: 23688078
Oncotarget. 2015 Jan 20;6(2):935-52
pubmed: 25473897
Cancer. 2014 Mar 15;120(6):833-9
pubmed: 25302607
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Front Immunol. 2019 May 07;10:990
pubmed: 31134073
Genes Dev. 2014 Jul 15;28(14):1578-91
pubmed: 25030697
Oncogene. 1998 Nov 26;17(21):2711-7
pubmed: 9840935
Cancer Res. 2005 Apr 1;65(7):2592-601
pubmed: 15805255
Cancer Res. 2008 May 15;68(10):3767-76
pubmed: 18483260
Nat Rev Cancer. 2010 Feb;10(2):116-29
pubmed: 20094046
Development. 2007 Jan;134(1):167-76
pubmed: 17164422
Cancer Cell. 2005 Sep;8(3):197-209
pubmed: 16169465
Nat Cell Biol. 2003 Jun;5(6):513-9
pubmed: 12766772
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Virchows Arch. 2002 Oct;441(4):380-4
pubmed: 12404063

Auteurs

Salah Boudjadi (S)

Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, Maryland.

Puspa Raj Pandey (PR)

Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, Maryland.

Bishwanath Chatterjee (B)

Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, Maryland.

Thanh Hung Nguyen (TH)

Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, Maryland.

Wenyue Sun (W)

Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, Maryland.

Frederic G Barr (FG)

Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, Maryland. barrfg@mail.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH